Equities

Agenus Inc

Agenus Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.84
  • Today's Change-0.150 / -2.50%
  • Shares traded980.29k
  • 1 Year change-75.67%
  • Beta1.3566
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments76193307
Total Receivables, Net262.741.52
Total Inventory------
Prepaid expenses8.101420
Other current assets, total2.373.193.17
Total current assets112213332
Property, plant & equipment, net16316491
Goodwill, net252525
Intangibles, net4.416.238.49
Long term investments------
Note receivable - long term------
Other long term assets5.671.786.87
Total assets314414466
LIABILITIES
Accounts payable614130
Accrued expenses484045
Notes payable/short-term debt000
Current portion long-term debt/capital leases118.531.06
Other current liabilities, total1369981
Total current liabilities256189157
Total long term debt172513
Total debt283314
Deferred income tax------
Minority interest126.3813
Other liabilities, total189255248
Total liabilities474475432
SHAREHOLDERS EQUITY
Common stock3.943.062.57
Additional paid-in capital1,7921,6451,520
Retained earnings (accumulated deficit)(1956)(1710)(1490)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.96)0.921.49
Total equity(160)(61)34
Total liabilities & shareholders' equity314414466
Total common shares outstanding201513
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.